Archive: CML Publications

2026 Clinical Papers

July

Introduction to the review series. Chronic myeloid leukemia in 2026
Radich J. Haematologica, July 2026
open access publication

Favorable tolerability of Asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia
Issa GC et al. Haematologica, July 2026 (epub ahead of print)
open access publication

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results
Cortes JE et al. Leukemia, July 2026 (epub ahead of print)
open access publication

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial
Kantarjian H et al. Leukemia, July 2026 (epub ahead of print)
open access publication

Diabetic patients with newly diagnosed chronic myeloid leukemia: TKI choice and early adverse events. A real-life survey with the Italian CML Network
Russo S et al. Eur J Haematol, July 2026 (epub ahead of print)

Development and external validation of a transcriptome-based multivariable prediction model for treatment-free remission in chronic myeloid leukemia
Alcazer V et al. J Clin Oncol, July 2026

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic-phase: Results of the Japan Adult Leukemia Study Group RE-STOP219 Study
Iriyama N et al. Br J Haematol, July 2026 (epub ahead of print)
open access publication

Olverembatinib: real progress in BCR::ABL1 leukemia?
Oehler VG et al. Haematologica, July 2026 (epub ahead of print)
open access publication

Frontline nilotinib versus dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on Agenzia Italiana del Formaco Monitoring Registries
Breccia M et al. Clin Lymphoma Myeloma Leuk, July 2026

Ponatinib safety profile: An analysis of 10 years of real-world experience
Jabbour E et al. Drug Saf, July 2026 (epub ahead of print)
open access publication

Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukemia
Fujita M and Ureshino H. Br J Haematol, July 2026

Real-world evidence-based study on treatment-free remission in chronic myeloid leukemia
Cheng F et al. J Natl. Compr Canc Netw, July 2026 (epub ahead of print)
open access publication

Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia
Yolcu A and Haznedaroglu IC. Expert Rev Hematol, April 2026 (epub ahead of print)

The care and cure of the leukemias in 2026
Kantarjian H et al. Am J Hematol, April 2026

Patients’ and healthcare providers’ views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study
Lokhorst DN et al. Oncologist, April 2026 – open access publication

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia
Basabrain, A.A.et al. Int. J Mol Sci, March 2026

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
Gagnon, L.L. et al. Leukemia, March 2026 – open access publication

March

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
Cortes JE et al. Blood, March 2026
open access publication

Imatinib outcomes in chronic myeloid leukemia across diverse healthcare settings: A systematic review and meta-analysis
Miranda-Galvis M et al. Blood Cancer J, March 2026
open access publication

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukemia
Claudiani S et al. Br J Haematol, March 2026 (epub ahead of print)
open access publication

Shared identity and patient care: adherence to guideline-recommended biomarker testing in chronic myeloid leukemia
Montano-Campos JF et al. J Natl Canc Netw, March 2026
open access publication

Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies
Radich JP et al. Haematologica, March 2026 (epub ahead of print)
open access publication

Imatinib and nilotinib are equally successful in achieving treatment-free remission
Cheng F et al. Blood Cancer J, March 2026
open access publication

Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations
Haddad FG et al. Expert Opin Pharmacother, March 2026 (epub ahead of print)

Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing
Oehler VG et al. Haematologica, March 2026 (epub ahead of print)
open access publication

Restless leg syndrome in chronic myeloid leukemia: an overlooked condition with a significant impact on health-related quality of life
Gürer T et al. Ann Hematol, March 2026
open access publication

Very long-term outcomes of chronic-phase chronic myeloid leukemia patients treated with imatinib: A 25-year real-world cohort study
Costa A et al. Br J Haematol, March 2026 (epub ahead of print)

Outcomes of patients treated with dasatinib 50 mg/d: A Pooled Analysis
Haddad FG et al. Clin Lymphoma Myeloma Leuk, March 2026 (epub ahead of print)

Five-year analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan
Takahashi N et al. Int J Hematol, March 2026 (epub ahead of print)
open access publication

Beyond ATP: asciminib and the allosteric path in CML
Abruzzese E et al. Blood, March 2026

ELN 2025 and somatic NGS in CML: a pragmatic framework for selective testing and interpretation beyond BCR::ABL1
Mishra S et al. Leuk Lymphoma, March 2026 (epub ahead of print)

February

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase
Lauseker M et al. Leukemia, February 2026 (epub ahead of print)
open access publication

A plain language summary of how the body processes a lower-dose nilotinib tablet (DanzitenTM) compared with the existing capsule (Tasigna®)
Mauro M et al. Future Oncol, February 2026

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study
Iurlo A et al. Cancer, February 2026
open access publication

Extended long-term follow-up and the survival of Stop Imatinib Study
Mahon FX et al. Blood Neoplasia, February 2026
open access publication

Leveraging model-informed drug development to predict asciminib efficacy in second-line treatment of chronic myeloid leukemia in chronic phase
Sy SKB et al. Clin Pharmacokinet, February 2026 (epub ahead of print)

Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparable cohort study
Cheng F et al. BMC Cancer, February 2026 (epub ahead of print)
open access publication

Second- and third-generation BCR-ABL tyrosine kinase inhibitors and the risk of pulmonary arterial hypertension: A prevalent new-user design
Jambon-Barbara C et al. Circulation, February 2026 (epub ahead of print)
open access publication

A BCR::ABL1 exon 13 variant leads to systematic underestimation of transcript level in the molecular monitoring of CML
Boucher L et al. Leuk Res, February 2026 (epub ahead of print)

Evolving therapeutic algorithms in chronic myeloid leukemia: Integrating efficacy, safety, and survivorship
Leyfman Y et al. Biomedicines, February 2025
open access publication

The importance of bone marrow biopsy for chronic myeloid leukemia classification – a case report
Gonçalves NY et al. HJ Hematop, February 2026
open access publication

Should you be afraid of the big bad wolf? A practical real-world review for the comfortable use of bosutinib in the therapy of chronic myeloid leukemia
Lipton JH. J Cancer Immunol, December 2025
open access publication

Secondary chronic myeloid leukemia in the blast phase with mixed phenotype after radiation therapy: A Case Report
Aoki M et al. EJHaem, February 2026
open access publication

January

Randomized phase 3 trial of Ropeginterferon alpha-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)
Burchert A et al. Leukemia, January 2026 (epub ahead of print)
open access publication

Risk factors and reasons for switching from front-line therapy in the Italian CML network: A cohort study
Breccia M et al. Br J Haematol, January 2026 (epub ahead of print)

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results
Réa D et al. Leukemia, January 2026 (epub ahead of print)

Management of chronic myeloid leukemia during pregnancy: Review of evidence and treatment algorithm
Haddad FG et al. Clin Lymphoma Myeloma Leuk, January 2026

Real-world outcomes with low-dose dasatinib (50 mg) in imatinib-resistant chronic myeloid leukemia chronic-phase: A retrospective analysis of efficacy and safety
Gangadaran N et al. Cancer Rep (Hobokken), January 2026
open access publication

Evaluating the safety of combining tyrosine kinase inhibitors with anticoagulants in chronic myeloid leukemia: A systematic review
Gameil A et al. Oncology, January 2026 (epub ahead of print)
open access publication

One-year consolidation with ponatinib 15 mg in chronic myeloid leukemia on deep molecular response with imatinib
Pérez-Lamas L et al. Ann Hematol, January 2026
open access publication

Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Ross DM. Leuk Lymphoma, January 2026 (epub ahead of print)

Introduction to a How I Treat series on chronic myeloid leukemia
Gotlib J. Blood January 2026

How I treat advanced phases of CML
Mauro MJ. Blood, January 2026

How I evaluate and treat resistance and relapse in CML
Soverini S and Castagnetti F. Blood, January 2026

How I individualize frontline treatment for chronic phase CML
Leyte-Vidal A and Shah NP. Blood, January 2026

How I approach hematopoietic stem cell transplantation for CML in a TKI world
Chalandon Y et al. Blood, January 2026

How I manage chronic myeloid leukemia during pregnancy
Abruzzese E, Chelysheva E. Blood January 2026

Advances of next-generation STAMP inhibitors in chronic myeloid leukemia
Costa A and Breccia M. Expert Opin Investig Drugs, January 2026

Drug resistance in chronic myeloid leukemia: The involvement of Galectin-1 and Galectin-3
Yildirim C. Mol Biol Rep, January 2026

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow
Patterson SD et al. Leukemia, January 2026 (epub ahead of print)
open access publication

An overview of chronic myeloid leukemia treatment:
From tyrosine kinase inhibitors to novel and emerging therapies
Sekar AJ et al. Eur J Haematol, January 2026 (epub ahead of print)
open access publication

Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia
Takahashi N et al. Eur J Clin Pharmacol, January 2026

Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia
Ureshino H and Kimura S. Expert Rev Hematol, January 2026 (epub ahead of print)

2026 Scientific Papers

July

Improved inter-lab precision after CML international scale adaptation: a 15-year history of BCR::ABL1 proficiency testing
Kim AS et al. Leukemia, July 2026 (epub ahead of print)
open access publication

Development and validation of an in-house one-step RT-qPCR method for the quantification of the BCR::ABL1 p210 transcripts
Damerchiloo F et al. Sci Rep, July 2026 (epub ahead of print)
open access publication

Measurable residual disease and the unresolved biology of leukemic stem cells
Bhartiya D et al. Stem Cell Rev Rep, July 2026 (epub ahead of print)

Genetic Profile, Treatment Response, and Outcomes of BCR::ABL1-Positive Mixed-Phenotype Acute Leukemia: A Study From the BCR::ABL1 Pathology Group
Shen Q., et al. Modern Pathology, May 2026
open access publication

June

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib compared with imatinib and nilotinib
Kok CH et al. Leukemia, June 2026 (epub ahead of print) – open access publication

Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity
Culen M et al. Haematologica, June 2026 (epub ahead of print) – open access publication

Localization of p210 BCR-ABL to the mitochondria promotes chronic myeloid leukemia cell proliferation through cIAP signaling
Ikegami A et al. FASEB J, June 2026

Prolonged BCR::ABL1 induction in the SCL-tTA mouse recapitulates gene expression signatures and therapeutic vulnerabilities of primary imatinib-resistant chronic myeloid leukemia
Shyamsunder P et al. Leukemia, June 2026 (epub ahead of print)

May

BCR-ABL drives transcriptional reprogramming of chronic myeloid leukemia cells for immune evasion through C/EBPβ
Lu X et al. MedComm (2020), April 2026 eCollection May 2026 – open access publication

Circular RNA in chronic myeloid leukemia
(Commentary on Papaioannou D. et al Blood, May 2026)
Gambacorti-Passerini C. Blood, May 2026

circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias
Papaioannou D et al. Blood, May 2026

Cytogenetic diversity of variant Philadelphia translocations in chronic myeloid leukemia
Tokac AGB et al. Int J Lab Hematol, May 2026 (epub ahead of print)
– open access publication

CD56(+)/CD38(+) neutrophils: Rapid and specific flow cytometric signature for chronic myeloid leukemia
Laganà A et al. Mediterr J Hematol Infect Dis, May 2026 – open access publication

Cracking the CODEX of the leukemic BM microenvironment
(Commentary on Li L. et al Blood, May 2026)
Duarte D et al. Blood, May 2026

High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression
Li L et al. Blood, May 2026

Reduced levels of ITGB1 cause activation of P38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib – novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled
Agrawal N et al. Cell Commun Signal, May 2026 (epub ahead of print)
– open access publication

April

Targeting the BCR::ABL1 kinase: Advances beyond imatinib in chronic myeloid leukemia
Naderi Z et al. Curr Hematol Malig Rep, April 2026

Targeting STAT5 via CRISP/Cas9 restores TKI sensitivity in resistant CML cells
Çelik B et al. Med Oncol, April 2026 – open access publication

Understanding drug resistance in chronic myeloid leukemia through the lens of leukemia stem cell states: insights from single-cell analyses
Krishnan V et al. Haematologica, April 2026 (epub ahead of print) – open access publication

An AI-enabled single-cell transcriptomic analysis pipeline for gene signature discovery in natural killer cells linked to remission outcomes in chronic myeloid leukemia
Borra S et al. Biology (Basel), April 2026 – open access publication

March

Chronic myeloid leukemia: have basophils gone the way of the Dodo bird?
Turcsanyi L et al. Leukemia, March 2026 (epub ahead of print)
open access publication

FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Li X et al. Cell Rep, March 2026
open access publication

Transcriptional readthrough precedes alternative splicing programs triggered in chronic myeloid leukemia cells imatinib
Podszywalow-Bartnicka P et al. Sci Adv, March 2026
open access publication

Treatment of K562 cells with ABL kinase inhibitors reveals differential metabolic profiles
Renukuntla P et al. Drug Res (Stuttg.), March 2026

Targeting mitochondrial vulnerabilities in chronic myeloid leukemia: From pathobiology to novel therapeutic opportunities
Caprino F et al. Cancers(Basel), March 2026
open access publication

Activated memory cytotoxic T-lymphocyte and T-cell receptor Vβ clonality predict treatment-free remission after TKI discontinuation in chronic-phase chronic myeloid leukemia: A 1-year prospective immune-monitoring study
Jo T et al. Int J Mol Sci, March 2026
open access publication

BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia
Park J et al. Leukemia, March 2026
open access publication

February

Intrinsic cellular resistance to BCR::ABL1 inhibitors
Cruz-Rodriguez N et al. Haematologica, February 2026 (epub ahead of print)
open access publication

ERK-mTOR crosstalk suppresses autophagy and upregulates proteasomal degradation pathway to confer chronic myeloid leukemia cells resistant to imatinib
Roy R et al. Exp Hematol, February 2026

High miR-202-5p expression at initial diagnosis is associated with tyrosine kinase inhibitor resistance in chronic myeloid leukemia – a result from a nested Case-Control Study
Nie ZY et al. EJHaem, February 2026
open access publication

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
Luukkainen K et al. Hemasphere, February 2026
open access publication

Peripheral blood neutrophil maturation as a predictor of treatment-free remission in CML
Fujita M et al. Int J Lab Hematol, February 2026 (epub ahead of print)

Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells
Atef B et al. Ann Hematol, February 2026
open access publication

Molecular background of Philadelphia chromosome dependent enhancement of cellular growth and tyrosine kinase inhibitor sensitivity
Hossain MF et al. Exp Hematol Oncol, February 2026
open access publication

ATTEC-mediated degradation of BCR-ABL in chronic myeloid leukemia cells
Wang Z et al. Eur J Med Chem, February 2026

Integrative multi-omics analysis of long non-coding RNA regulatory networks in chronic myeloid leukemia resistance and leukemic stem cell persistence
Soltani I et al. Comput Biol Chem, February 2026

Asciminib and pulsed ATRA as post-remission therapy in T3151I mutated PML_RARA-positive blast crisis of chronic myeloid leukemia
Mazzarella R et al. Ann Hematol, February 2026
open access publication

Quantitative reverse transcription PCR compared with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1
Zhou T et al. J Clin Pathol, February 2026

Dual proteasome and histone deacetylase inhibition overcomes tyrosine kinase inhibitor resistance in breakpoint cluster region: Abdelson 1-driven leukaemia cell lines
Okabe S et al. J Cell Mol Med, February 2026
open access publication

January

Hsp-70 Bim interaction mediated mitophagy as a potential therapeutic target for CML stem cells
Song T et al. Stem Cell Reports, January 2026
open access publication

Enhanced detection of splice-altering variants in hematologic malignancies using targeted RNA-sequencing data
Maqsood M et al. J Mol Diagn, January 2026

Identification of a Mushashi2 translocation as a novel oncogene in myeloid leukemia
Spinler K et al. Elife, January 2026
open access publication

Quantitative reverse transcription PCR completed with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1
Zhou T et al. J Clin Pathol, January 2026 (epub ahead of print)

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow
Patterson SD et al. Blood, January 2026 (epub ahead of print)
open access publication

Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential
Chen N et al. Haematologica, January 2026 (epub ahead of print)
open access publication

2026 Low- and Middle-Income Countries Publications

Worldwide Publications of Interest

Chronic myeloid leukemia in low- and middle-income countries
Mahon FX et al. N Engl J Med, June 2026

Chronic myeloid leukemia in resource-limited settings: Navigating treatment challenges amit limited tyrosine kinase inhibitor access
Aamir Z et al. J Int Med Res, June 2026 – open access publication

Benefits and perils of generic drugs for hematologic neoplasms and their use in low- and middle-income countries: a narrative review
Malhotra H. and Burli A., Blood Global Hematology, June 2026 – open access publication

Treatment-free remission in chronic myeloid leukemia in low- and middle-income countries
Annamalay A et al. N Engl J Med, March 2026
open access publication

Next-generation sequencing from chronic myeloid leukemia dried blood spots: Insights and implications for global oncology
Oehler VG et al. Leukemia, January 2026 (epub ahead of print)

CML Publications from Africa

BCR-ABL1 transcript variants in chronic myeloid leukemia patients in Africa: A systematic review
Emeline Oloume M et al. Health Sci Rep, July 2026
open access publication

Long-term survival and successful pregnancy in a Nigerian women with concurrent diagnosis of non-Hodgkin lymphoma and chronic myeloid leukemia:
a care report
Ahmed IO et al. J Med Case Rep, January 2026
open access publication

CML Publications from the Middle East

Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review
Özmen D et al. Leuk Res, July 2026

Genetic and non-genetic correlates of imatinib pharmacokinetics and side effects of imatinib in Palestinian patients with chronic myeloid leukemia
Adawi DH et al. Biochem Genet, April 2026

CML Publications from Asia

Study on efficacy and safety of dasatinib 50 mg in newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP): Experience from a tertiary care hospital
Banarjee A et al. Indian J Hematol Blood Transfus, July 2026

Optimizing treatment-free remission (TFR) in chronic myeloid leukemia: Challenges and a modified monitoring strategy – real-world data from Eastern India
Parihar M et al. Indian J Haematol Blood Transfus, July 2026

Decoding BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Implications for tyrosine kinase inhibitor resistance in a South Asian population
Sharif F et al. Hematol Transfus Cell Ther, July 2026 (epub ahead of print)
open access publication

Clinical significance of the S348I mutation in BCR-ABL as a dominant variant in Indonesian CML patients under tyrosine kinase inhibitor therapy: A Cohort Study
Harjianti T et al. Asian Pac J Cancer Prev, February 2026
open access publication

Impact of bone marrow fibrosis on the outcomes of chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors
Fayyaz F et al. Indian J Hematol Blood Transfus, January 2026

CML Publications from Latin America

Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study
Emiliano EG et al. Hematol Transfus Cell Ther, May 2026 (epub ahead of print)
– open access publication

Breaking barriers: Reducing cost and overcoming challenges in BCR::ABL1 monitoring for chronic myeloid leukemia in Brazil
Etges APBDS et al. JCO Glob Oncol, April 2026 - open access publication

Real-life data of patients with chronic myeloid leukemia in Amazonas
Abreu RS et al. BMC Cancer, March 2026 (epub ahead of print)
open access publication

2026 Pediatric CML Publications

July

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukemia: Towards practical implementation and interpretation of measured plasma concentrations
Lensker P et al. Clin Pharmacokinet, July 2026 – open access publication

Treatment patterns and outcomes of pediatric chronic myeloid leukemia in a Brazilian multicentre cohort
da Silva MEM et al. Pediatr Blood Cancer, July 2026 (epub ahead of print)

June

Prepubertal initiation of imatinib is associated with reduced final height in children with chronic myeloid leukemia
Sadanand R et al. Pediatr Hematol Oncol, June 2026 (epub ahead of print)

May

Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Towards practical implementation and interpretation of measured plasma concentrations
Lensker P et al. Clin Pharmacokinet, May 2026 (epub ahead of print)
– open access publication

April

Prevalance and characterization of germline RAS pathway variants in children with chronic myeloid leukemia
Ghete T et al. Leukemia, April 2026 (epub ahead of print) – open access publication

March

Long-term outcomes of chronic myeloid leukemia in children and adolescents – real-world data from a single-institute in Taiwan
Yang YN et al. J Farmos Med Assoc, March 2026
open access publication

January

How I treat chronic myeloid leukemia in children and adolescents
(Chen J et al. Blood, January 2026)

Predictors of response to imatinib therapy and long-term outcomes in pediatric and adolescent patients with CML
(Saha S et al. Cancer Rep Hoboken, January 2026)

Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
(Yang Y et al. Jpn J Clin Oncol, January 2026)

CML and COVID-19

Immune response to SARS-CoV-2 vaccination among chronic myeloid leukemia patients on tyrosine kinase inhibitors
Cheong CS et al. Ann Acad Med Singap, April 2026 (epub ahead of print) – open access publication

Previous Years CML Publications

2025 CML Publications

2024 CML Publications

2023 CML Publications